Avivagen Inc. (VIV.V)
| Previous Close | 0.0050 |
| Open | 0.0050 |
| Bid | 0.0050 x 0 |
| Ask | 0.0050 x 0 |
| Day's Range | 0.0050 - 0.0050 |
| 52 Week Range | 0.0050 - 0.0400 |
| Volume | |
| Avg. Volume | 15,209 |
| Market Cap | 388,474 |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | Apr 18, 2024 - Apr 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Avivagen Announces New 500Kg Order for OxC-beta™
OTTAWA, Ontario, October 17, 2023--Avivagen Inc. (TSXV.VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce a 500kg order for OxC-beta™. The purchase follows a 500kg order in July from the same customer, based in Taiwan, for use within the sow ma
- Business Wire
Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2023
OTTAWA, Ontario, September 29, 2023--Avivagen Inc. (TSXV:VIV) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2023.
- Business Wire
Avivagen Provides Corporate Updates
OTTAWA, Ontario, July 31, 2023--Avivagen Inc. (TSXV.VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today announces several corporate updates, relating to the allowances of patents, a waiver of an interest payment on its senior secured debentures and the continuat
